par Stupp, R;Mason, Warren P;van den Bent, M J;Weller, M;Fisher, Barbara;Taphoorn, M J B;Belanger, Karl;Brandes, Alba A;Marosi, C;Bogdahn, Ulrich;Curschmann, Jürgen;Janzer, Robert C;Ludwin, Samuel K;Gorlia, Thierry;Allgeier, Anouk 
;Lacombe, Denis;Cairncross, J G;Eisenhauer, Elizabeth;Mirimanoff, René Olivier;European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, ;National Cancer Institute of Canada Clinical Trials Group,
Référence The New England journal of medicine, 352, 10, page (987-996)
Publication Publié, 2005-03
;Lacombe, Denis;Cairncross, J G;Eisenhauer, Elizabeth;Mirimanoff, René Olivier;European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, ;National Cancer Institute of Canada Clinical Trials Group, Référence The New England journal of medicine, 352, 10, page (987-996)
Publication Publié, 2005-03
Article révisé par les pairs
| Titre: |
|
| Auteur: | Stupp, R; Mason, Warren P; van den Bent, M J; Weller, M; Fisher, Barbara; Taphoorn, M J B; Belanger, Karl; Brandes, Alba A; Marosi, C; Bogdahn, Ulrich; Curschmann, Jürgen; Janzer, Robert C; Ludwin, Samuel K; Gorlia, Thierry; Allgeier, Anouk; Lacombe, Denis; Cairncross, J G; Eisenhauer, Elizabeth; Mirimanoff, René Olivier; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, ; National Cancer Institute of Canada Clinical Trials Group, |
| Informations sur la publication: | The New England journal of medicine, 352, 10, page (987-996) |
| Statut de publication: | Publié, 2005-03 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| MeSH keywords: | Adrenal Cortex Hormones -- therapeutic use |
| Adult | |
| Aged | |
| Antineoplastic Agents, Alkylating -- adverse effects | |
| Antineoplastic Agents, Alkylating -- therapeutic use | |
| Brain Neoplasms -- drug therapy | |
| Brain Neoplasms -- mortality | |
| Brain Neoplasms -- radiotherapy | |
| Chemotherapy, Adjuvant | |
| Dacarbazine -- adverse effects | |
| Dacarbazine -- analogs & derivatives | |
| Dacarbazine -- therapeutic use | |
| Disease Progression | |
| Female | |
| Glioblastoma -- drug therapy | |
| Glioblastoma -- mortality | |
| Glioblastoma -- radiotherapy | |
| Humans | |
| Male | |
| Middle Aged | |
| Proportional Hazards Models | |
| Radiotherapy, Computer-Assisted -- adverse effects | |
| Survival Analysis | |
| Note générale: | Clinical Trial |
| Clinical Trial, Phase III | |
| Journal Article | |
| Multicenter Study | |
| Randomized Controlled Trial | |
| Research Support, Non-U.S. Gov't | |
| Research Support, U.S. Gov't, P.H.S. | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0028-4793 |
| info:doi/10.1056/NEJMoa043330 | |
| info:pii/352/10/987 | |
| info:pmid/15758009 |
